Equities

Liquidia Corp

Liquidia Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)10.30
  • Today's Change-0.33 / -3.10%
  • Shares traded1.00m
  • 1 Year change+62.85%
  • Beta0.1969
Data delayed at least 15 minutes, as of Nov 13 2024 20:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments849357
Total Receivables, Net4.065.022.99
Total Inventory------
Prepaid expenses2.161.510.79
Other current assets, total------
Total current assets9010061
Property, plant & equipment, net6.186.257.43
Goodwill, net3.903.903.90
Intangibles, net3.433.734.39
Long term investments------
Note receivable - long term------
Other long term assets151616
Total assets11812994
LIABILITIES
Accounts payable1.402.201.07
Accrued expenses146.425.95
Notes payable/short-term debt000
Current portion long-term debt/capital leases2.720.180.31
Other current liabilities, total----0
Total current liabilities198.807.33
Total long term debt432011
Total debt462011
Deferred income tax------
Minority interest------
Other liabilities, total9.019.9310
Total liabilities713928
SHAREHOLDERS EQUITY
Common stock0.070.060.05
Additional paid-in capital476441375
Retained earnings (accumulated deficit)(429)(351)(310)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity479065
Total liabilities & shareholders' equity11812994
Total common shares outstanding696552
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.